Patent · US Active

Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereof

US9499588B2 · kind B2 · utility

8Cited by

2References

6Claims

0Family size

Assignee

The Board of Regents of the University of Texas System · US

Inventors

Peter Mason · Somerville, US
Tomohiro Ishikawa · Rochester, US

Key dates

Filing date	Jul 22, 2011
Grant date	Nov 22, 2016
Priority date	—
Expiry date	Jul 22, 2031

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides flavivirus vaccines that comprise live-attenuated flaviviruses and methods of making and using these vaccines. The flavivirus vaccines described herein possess higher potency due to in situ production of additional immunogens in a way that mimics viral infection and the vaccines have potential for higher potency, reducing costs for production and delivery.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.